David R. Bauer
Lawyers
Filters
Novo Nordisk proposed $9.1 billion acquisition of Metsera
We are advising Novo Nordisk on the transaction
GSK exclusive license agreement with Empirico
We advised GSK on the transaction
RAPT Therapeutics $250 million follow-on offering
The shares are listed on the Nasdaq Global Market
Nurix Therapeutics $250 million stock offering
The stock is listed on the Nasdaq Global Market
Esperion Therapeutics follow-on offering
The shares are listed on Nasdaq
Turn Therapeutics direct listing
We advised Turn Therapeutics on its Nasdaq listing
Neptune $368 million IPO
The shares are listed on the New York Stock Exchange
Amulet Capital Partners sale of SSI Strategy to Clinigen
We are advising Amulet Capital Partners and SSI Strategy on the sale
Medtronic €1.5 billion notes offering
The investment-grade notes are due 2030 and 2045
MBX Biosciences $200 million follow-on offering
The shares are listed on the Nasdaq Global Select Market